Trinity biotech to begin european pre-pivotal trial to optimize its cgm sensor

Dublin, june 24, 2024 (globe newswire) -- trinity biotech plc (nasdaq: trib) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to advance its next generation continuous glucose monitoring (“cgm”) solution towards market launch. since acquiring the cgm technology earlier in the year, trinity biotech has been working on further innovations and improvements to the original device. the company has now received regulatory approval to conduct its initial european pre-pivotal trial that will inform the larger pivotal trial that will be required for product registration and launch.
TRIB Ratings Summary
TRIB Quant Ranking